volume 7, issue 2, P153-157 2014
DOI: 10.15283/ijsc.2014.7.2.153
View full text

Abstract: Background:Engineered blood has the greatest potential to combat a predicted future shortfall in the blood supply for transfusion treatment. The production of red blood cells from hematopoietic stem cells in the laboratory is possible but the mass production of red blood cells to the level present in a blood transfusion unit is currently not possible. The proliferation capacity of the immature red blood cell will need to be increased to enable mass production. This work focused on the hypothesis that exogenous…

Expand abstract